Clinical trials: Insomnia, Primary
Sleep Initiation and Maintenance Disorders, Insomnia
Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year
The purpose of the study is to assess efficacy and safety of eplivanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- EPLILONG (NCT00253903)
- Testing
- eplivanserin (SR46349)
- Where
- 14 sites in United States, Argentina and 12 more
- Volunteers
- 1,155 people
- Sponsor
- Sanofi
Primary Insomnia
VEC-162 Study in Adult Patients With Primary Insomnia
The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.
- Trial name
- NCT00548340
- Testing
- VEC-162 20 mg, VEC-162 50 mg
- Where
- 35 sites in United States
- Volunteers
- 322 people
- Sponsor
- Vanda Pharmaceuticals
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients
KI1001(Circadin®, Prolonged release tablet which contains melatonin) has showed its efficacy to improve sleep quality in over 55 years old primary insomnia patients.
- Trial name
- NCT01450228
- Testing
- KI1001
- Where
- 10 sites in South Korea
- Volunteers
- 170 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Primary Insomnia
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
The purpose of this study is to investigate and evaluate the efficacy of Eszopiclone in Japanese participants with primary insomnia.
- Trial name
- NCT00770510
- Testing
- Eszopiclone 1 mg, Eszopiclone 2 mg, Eszopiclone 3 mg
- Where
- 20 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Eisai Co., Ltd.
Primary Insomnia
Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties
Primary objective: To assess the efficacy of eplivanserin 5mg/day in comparison to placebo after 6 weeks of treatment on sleep maintenance of insomniac patients, as measured by Polysomnography Wake Time After Sleep Onset…
- Trial name
- ECLIPSE (NCT00805350)
- Testing
- Eplivanserin
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 637 people
- Sponsor
- Sanofi
Insomnia
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia
The primary objective of the study is to evaluate the safety and tolerability of Neu-P11, following the administration of multiple ascending oral doses (2, 5, 20, 50 mg or matching placebo) given nightly over 2 periods of 5 days…
- Trial name
- NCT01114126
- Testing
- Neu-P11
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Primary Insomnia
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia
The purpose of this study is to further explore an effective dose range of PD0200390 for the treatment of patients with insomnia.
- Trial name
- NCT00551148
- Testing
- PD 0200390
- Where
- 16 sites in United States
- Volunteers
- 92 people
- Sponsor
- Pfizer
Primary Insomnia
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
- Trial name
- NCT00266344
- Testing
- MK0928, gaboxadol / Duration of Treatment 3 Weeks
- Volunteers
- 520 people
- Sponsor
- H. Lundbeck A/S
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus
The purpose of this study is to assess efficacy and safety of volinanserin in the population of patients complaining of sleep maintenance insomnia.
- Trial name
- SAMS12 (NCT00495885)
- Testing
- volinanserin (M100907)
- Where
- 16 sites in United States, Brazil and 14 more
- Volunteers
- 848 people
- Sponsor
- Sanofi
Primary Insomnia
Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs
This will be a multi-center, randomized, blinded, comparative, placebo-controlled, 4 arm crossover study in patients with primary insomnia.
- Trial name
- NCT00683436
- Testing
- Adipiplon, Ambien CR
- Where
- 9 sites in United States
- Volunteers
- 84 people
- Sponsor
- Neurogen Corporation
Insomnia
An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)
The purpose of this study is to evaluate the safety and effectiveness of MK0928 for insomnia (a sleep disorder).
- Trial name
- NCT00103818
- Testing
- gaboxadol
- Volunteers
- 900 people
- Sponsor
- H. Lundbeck A/S
Sleep Initiation and Maintenance Disorders, Insomnia
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
This study is designed to find the optimal (best) doses of GW679769 that promote sleep onset and maintain sleep during two consecutive nights of dosing without significant next-day thinking impairment and drowsiness in subjects…
- Trial name
- NCT00280436
- Testing
- GW679769
- Where
- 26 sites in United States
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Sleep Initiation and Maintenance Disorders
Efficacy Study of LY2422347 to Treat Insomnia
The purpose of this study is to determine whether a compound known as LY2422347 is effective in treating people diagnosed with primary insomnia (difficulty sleeping with no other significant contributing factor, such as…
- Trial name
- NCT00259311
- Testing
- LY2422347
- Where
- 22 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Insomnia
A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia
To demonstrate efficacy and characterize the dose response relationship of PD 0200390 on subjective wake after sleep onset in subjects with primary insomnia.
- Trial name
- NCT00569972
- Testing
- PD 0200390
- Where
- 84 sites in United States, Canada
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Pfizer
Insomnia
Effects of Insomnia on Simulated Driving (MK-0000-183-00)
This is a double-blind, parallel design study in elderly primary insomnia patients and demographically matched controls. The objectives if this study are primarily: 1.
- Trial name
- NCT01209728
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia Disorder
Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder
The main purpose of this study is to evaluate the efficacy and safety of YZJ-1139 in the short-term treatment of primary chronic insomnia, explore the optimal effective dose, and provide the basis for phase III clinical trials
- Trial name
- NCT06680505
- Testing
- YZJ-1139 10mg, YZJ-1139 20mg, YZJ-1139 40mg
- Where
- 33 sites in China
- Volunteers
- 300 people
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Primary Insomnia
Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia
The objective of this study is to determine the efficacy of a portable biofeedback device on improving sleep latency and other sleep variables such as nocturnal awake time and daytime functioning in persons with primary insomnia.
- Trial name
- NCT00415714
- Testing
- Portable Biofeedback
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Helicor
Bladder Function
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
This is an observational, physiology pilot study of subjects with overactive bladder, insomnia and normal subjects. No study drug will be given. All subjects will complete a one week sleep diary and a 3-day bladder diary.
- Trial name
- Nocturia Plt 1 (NCT01029015)
- Testing
- cystometry, polysomnography
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Sleep Initiation and Maintenance Disorders
To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
This study to evaluate the effects of SB-649868 (10, 30 mg and 60 mg) on sleep continuity, PSG sleep recordings, subjective sleep assessment, and daytime cognitive function in subjects with primary insomnia
- Trial name
- NCT00426816
- Testing
- SB-649868
- Where
- 10 sites in Germany
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Insomnia
Safety and Efficacy Study of APD125 in Patient With Insomnia
The purpose of this study is to determine the effects of APD125 in patients with sleep maintenance insomnia.
- Trial name
- NCT00452179
- Testing
- APD125
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Arena Pharmaceuticals